Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples